N-Acetyl Selank Amidate
A terminally protected, longer-acting analogue of the tuftsin-derived heptapeptide Selank, studied in research models for anxiolytic, GABAergic and neurotrophic activity.
What it is
N-Acetyl Selank Amidate (often shortened to NA-Selank) is a synthetic heptapeptide and a second-generation analogue of Selank, itself a stabilised derivative of the natural immunomodulatory tetrapeptide tuftsin. The parent Selank carries the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro; the acetylated, amidated variant adds an N-terminal acetyl group and a C-terminal amide to give the sequence Ac-Thr-Lys-Pro-Arg-Pro-Gly-Pro-NH2. It belongs to the same Russian family of neuro-active research peptides as Semax and its own acetyl-amidate analogue.
The two terminal modifications are the whole point of the molecule. The N-terminal acetyl group blocks aminopeptidase cleavage and the C-terminal amide protects against carboxypeptidase attack, so the peptide resists the exopeptidases that rapidly clear unmodified Selank. Vendor and secondary-source material describes this as extending the effective plasma half-life from roughly 20-30 minutes for Selank into a substantially longer window, which is the rationale for studying the amidate as a more persistent probe of the same pathways. It is confirmed on PubChem as CID 133082488, molecular formula C35H59N11O10. Supplied strictly for laboratory research use only, not for human or veterinary use.
How it works
Selank and its analogues are not classical benzodiazepines: they do not bind the benzodiazepine site directly. Instead the research literature on the parent peptide points to a multi-pathway profile. Selank appears to act as a concentration-dependent modulator of GABA-ergic tone, to slow the breakdown of endogenous enkephalins by inhibiting enkephalin-degrading enzymes, and to shift expression of neurotrophic and cytokine genes. In the foundational clinical comparison against the benzodiazepine medazepam, Selank-treated patients showed rising leucine-enkephalin levels that tracked with improvement in anxiety scores, a neurochemical change absent in the benzodiazepine arm.
On the neurotrophic side, intranasal Selank was shown to regulate brain-derived neurotrophic factor (BDNF) in the rat hippocampus: single doses of 250 and 500 mcg/kg raised Bdnf mRNA within 3 hours and increased BDNF protein at 24 hours (Inozemtseva et al., 2008). On the GABA-receptor side, a Frontiers in Pharmacology study in IMR-32 neuroblastoma cells found that Selank alone did not change GABAergic gene transcription, but strongly reshaped it in combination with other agents, consistent with a modulatory rather than a directly transcription-driving role. N-Acetyl Selank Amidate is studied as a metabolically hardened version of this same pharmacology, on the premise that longer residence time lets these mechanisms be probed over an extended window.
What the research shows
Most controlled, quantitative data are on the parent Selank rather than on the acetyl-amidate analogue specifically, so the numbers below are foregrounded as Selank findings and should be read as the mechanistic backdrop for NA-Selank. They span the anxiolytic behaviour, the neurotrophic (BDNF) signal, and the GABAergic gene-expression work, each with a real published source.
| Metric | Result | Model or study | Source |
|---|---|---|---|
| Elevated plus maze, open-arm time (chronic stress) | 40.8 s with Selank + diazepam vs 4.6 s saline; 15.5 s Selank alone | Wistar rats, 300 mcg/kg intranasal Selank, 14-day course, unpredictable chronic mild stress | Kozlovskii et al., 2017 (PMC5322660) |
| Bdnf mRNA in hippocampus | Increased 3 h after dosing | Rat, intranasal Selank 250 and 500 mcg/kg | Inozemtseva et al., 2008 (PMID 18841804) |
| BDNF protein in hippocampus | Increased 24 h after dosing at both doses | Rat, intranasal Selank 250 and 500 mcg/kg | Inozemtseva et al., 2008 (PMID 18841804) |
| GABAergic gene expression, Selank alone | No significant change in the 84 genes studied | IMR-32 human neuroblastoma cells | Filatova et al., 2017 (Front. Pharmacol.) |
| GABAergic gene expression, Selank + olanzapine | 35 of 69 genes changed; JUNB -6.6-fold, CSF2 -6.2-fold, GABRA5 +1.86-fold | IMR-32 human neuroblastoma cells | Filatova et al., 2017 (Front. Pharmacol.) |
| Clinical anxiolysis | Comparable to medazepam; added antiasthenic and mild psychostimulant effects, rising leu-enkephalin | 62 patients with generalised anxiety disorder and neurasthenia | Zozulia et al., 2008 |
Read the numbers as Selank data
The quantitative endpoints above were generated with the parent peptide Selank. N-Acetyl Selank Amidate is the terminally protected analogue studied on the premise of longer metabolic stability; direct head-to-head potency figures for the amidate are not established in the peer-reviewed literature.
At a glance
| Class | Synthetic tuftsin-analogue heptapeptide (acetylated, amidated Selank analogue) |
| Molecular weight | 793.9 Da |
| CAS | 864070-44-0 |
| Vial | Lyophilised powder, reconstitute before use |
Molecular identity confirmed on PubChem (CID 133082488): molecular formula C35H59N11O10, sequence Ac-Thr-Lys-Pro-Arg-Pro-Gly-Pro-NH2.
Compared with Selank
The parent Selank has a molecular weight of about 751.9 Da (CAS 129954-34-3) and an unprotected N- and C-terminus, which leaves it open to rapid exopeptidase clearance. N-Acetyl Selank Amidate keeps the same core heptapeptide but caps both ends, raising the molecular weight to about 793.9 Da and, per vendor and secondary sources, extending the metabolic window. The pharmacological hypotheses, GABAergic modulation, enkephalin stabilisation and BDNF-driven neurotrophic signalling, carry over from Selank; the amidate is essentially a stability-hardened tool for studying the same biology over a longer time course.
Preparing it
N-Acetyl Selank Amidate is supplied as a lyophilised powder and is reconstituted with bacteriostatic or sterile water before use in research. See the reconstitution guide for mixing and storage, and the concentration guide for working out volume per target amount. Store lyophilised vials cold and keep reconstituted solution refrigerated at 2-8 C.
Where to go next
Parent Selank
The unmodified heptapeptide behind this analogue, with the core anxiolytic and cognitive research.
Read about SelankThe science
Mechanism background for neuro-active peptides and the pathways behind anxiolytic and cognitive research.
Explore the scienceIn the store
Search the catalogue for Selank and related compounds.
View in storeOrder This Peptide From Peptide.ST
Research-grade N-Acetyl Selank Amidate, third-party tested to high purity and shipped with a certificate of analysis. Strictly for laboratory research use.